Drug Trial Radar · NCT06053242
Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain
Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
May 21, 2024
Primary completion
Jan 20, 2027
Study completion Aug 20, 2027
Sponsor
- Lead sponsor
- Creative Medical Technology Holdings IncIndustry
- Sponsor type
- Industry
- First posted
- Sep 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The brief purpose of this research study is to learn about the safety, tolerability, and efficacy of paraspinal intramuscular injection of CELZ-201-DDT in patients with chronic lower back pain.
Conditions
- Chronic Low-back Pain
- Degenerative Disc Disease
Interventions
CELZ-201-DDTDrug
Subjects enrolled in the trial will receive CELZ-201-DDT at the specified dose into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
PlaceboOther
Subjects will receive a placbeo injection into the lumbar paraspinal musculature. Each subject will receive a total of six injections, three injections on each side, under direct ultrasound guidance.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate safety of CELZ-201-DDT administered as intramuscular injections in subjects experiencing chronic lower back pain at a low, medium, or high dose.Time frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Spine and Wellness Centers of America
Aventura, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.